APA (7th ed.) Citation

Enrique Casado, Jose Rosas, Carlos Rubio-Terres, Dario Rubio-Rodriguez, Mitra Boolell, & Ignacio Aristegui. (2023). Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain. Becaris Publishing Limited.

Chicago Style (17th ed.) Citation

Enrique Casado, Jose Rosas, Carlos Rubio-Terres, Dario Rubio-Rodriguez, Mitra Boolell, and Ignacio Aristegui. Cost-effectiveness of Weekly Gastro-resistant Risedronate 35 Mg, Compared with Weekly Alendronate 70 Mg Tablets, in the Treatment of Postmenopausal Osteoporosis in Spain. Becaris Publishing Limited, 2023.

MLA (9th ed.) Citation

Enrique Casado, et al. Cost-effectiveness of Weekly Gastro-resistant Risedronate 35 Mg, Compared with Weekly Alendronate 70 Mg Tablets, in the Treatment of Postmenopausal Osteoporosis in Spain. Becaris Publishing Limited, 2023.